# Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer

> **NCT07528430** · — · NOT_YET_RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 450 (estimated)

## Conditions studied

- Pancreatic Cancer, Advanced or Metastatic

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07528430
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2032-06
- **Final completion:** 2032-07
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07528430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07528430, "Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07528430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*